miR-489-3p inhibits TLR4/NF-κB signaling to prevent inflammation in psoriasis

Yujian Ye1, Ping Wang1, Fangmei Zhou2

  • 1Department of Dermatology, The Third People's Hospital of Hangzhou, Hangzhou, Zhejiang 310009, P.R. China.

Insights

MicroRNA-489-3p is downregulated in psoriasis, promoting inflammation by targeting Toll-like receptor 4. Restoring miR-489-3p may offer a new therapeutic strategy for psoriasis treatment.

Area of Science:

  • Dermatology
  • Molecular Biology
  • Immunology

Background:

  • Psoriasis is a chronic inflammatory skin condition with unknown causes.
  • MicroRNAs (miRs) are crucial in early psoriasis development and potential therapeutic targets.

Purpose of the Study:

  • To investigate the role of microRNA-489-3p (miR-489-3p) in psoriasis.
  • To determine if miR-489-3p targets Toll-like receptor 4 (TLR4) and affects inflammatory pathways.

Main Methods:

  • Quantitative PCR and Western blot to measure miR-489-3p, TLR4, and NF-κB levels.
  • Bioinformatics and luciferase assays to confirm miR-489-3p targeting of TLR4.
  • Cell viability, cell cycle, and proliferation assays in human keratinocytes (HaCaT) with miR-489-3p manipulation and TLR4 silencing.

Main Results:

  • miR-489-3p expression was significantly lower in psoriasis patients.
  • miR-489-3p directly targets and downregulates TLR4 expression.
  • Overexpression of miR-489-3p inhibited the TLR4/NF-κB pathway, reducing keratinocyte proliferation and inflammation.
  • TLR4 silencing reversed the inhibitory effects of miR-489-3p.

Conclusions:

  • miR-489-3p plays a key role in psoriasis pathogenesis by targeting TLR4 and modulating inflammatory responses.
  • miR-489-3p is a potential prognostic biomarker and therapeutic target for psoriasis.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.7K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
272
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K